Literature DB >> 10631194

Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis.

H Logginidou1, X Ao, I Russo, E P Henske.   

Abstract

OBJECTIVE: To determine whether renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis (LAM) express estrogen receptor (ER) and progesterone receptor (PR).
DESIGN: Retrospective study of archival tissue. PATIENTS: Twelve women with LAM and angiomyolipomas.
SETTING: Fox Chase Cancer Center.
INTERVENTIONS: ER and PR expression was studied using immunohistochemistry. The hormonal status of the patients at the time of resection of the angiomyolipoma was determined.
RESULTS: Ten of the angiomyolipomas had ER immunoreactivity (83%), and all 12 had PR immunoreactivity (100%). The ER and PR positivity was in the smooth muscle component of the angiomyolipomas only. For five women, pulmonary LAM specimens were also available; two were ER positive (40%), and all five were PR positive (100%). All four angiomyolipomas from women receiving progesterone therapy were ER and PR positive. One tumor from a woman receiving tamoxifen was ER negative and strongly PR positive. One woman was pregnant; her tumor was ER and PR positive.
CONCLUSIONS: ER and PR expression is frequent in renal angiomyolipoma cells from women with LAM. PR was more consistently present than ER in angiomyolipomas and in LAM. Our data suggest that angiomyolipoma growth could be affected by hormonal factors. If the growth of LAM-associated angiomyolipomas slows during hormonal therapy, there are two potential implications for LAM patients: first, angiomyolipoma size could serve as a measurable indication of response to hormonal therapy; and second, surgical removal of angiomyolipomas might be avoided in some cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10631194     DOI: 10.1378/chest.117.1.25

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

Review 1.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

2.  Sporadic subcutaneous angiomyolipoma with expression of estrogen and progesterone receptors.

Authors:  Gaetano Magro; Salvatore Lanzafame
Journal:  Virchows Arch       Date:  2006-11-24       Impact factor: 4.064

3.  Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.

Authors:  Yang Sun; Erik Zhang; Taotao Lao; Ana M Pereira; Chenggang Li; Li Xiong; Tasha Morrison; Kathleen J Haley; Xiaobo Zhou; Jane J Yu
Journal:  Horm Cancer       Date:  2014-07-29       Impact factor: 3.869

4.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 5.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.

Authors:  Hilaire C Lam; Julie Nijmeh; Elizabeth P Henske
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

6.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

7.  The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Authors:  Jay H Ryu; Joel Moss; Gerald J Beck; Jar-Chi Lee; Kevin K Brown; Jeffrey T Chapman; Geraldine A Finlay; Eric J Olson; Stephen J Ruoss; Janet R Maurer; Thomas A Raffin; Hannah H Peavy; Kevin McCarthy; Angelo Taveira-Dasilva; Francis X McCormack; Nilo A Avila; Rosamma M Decastro; Susan S Jacobs; Mario Stylianou; Barry L Fanburg
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

8.  Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.

Authors:  Chenggang Li; Na Li; Xiaolei Liu; Erik Y Zhang; Yang Sun; Kouhei Masuda; Jing Li; Julia Sun; Tasha Morrison; Xiangke Li; Yuanguang Chen; Jiang Wang; Nagla A Karim; Yi Zhang; John Blenis; Mauricio J Reginato; Elizabeth P Henske; Jane J Yu
Journal:  JCI Insight       Date:  2016-11-17

Review 9.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

Review 10.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.